European drug companies lobby for protections if there are problems with new Covid-19 vaccines

European vaccine makers want EU exemptions that would protect them if there are problems with new Covid-19 vaccines, and low interest rates have helped US homebuilder stocks surge to record highs. Plus, the FT’s James Fontanella-Khan explains why Ant Group chose to list its potentially record setting IPO outside the US. 

Covid-19 vaccine makers lobby EU for legal protection

Low rates help propel US homebuilder stocks to record highs

Ant Group reveals $2.6bn profit as it files for blockbuster IPO

See for privacy and opt-out information.

A transcript for this podcast is currently unavailable, view our accessibility guide.

Get alerts on FT News Briefing when a new story is published

Copyright The Financial Times Limited 2020. All rights reserved.
Reuse this content (opens in new window)

Comments have not been enabled for this podcast.

Follow the topics in this podcast